Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Lisata Therapeutics (LSTA) over the last 10 years, with Q2 2025 value amounting to $10000.0.

  • Lisata Therapeutics' Gains from Investment Securities changed N/A to $10000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $385000.0, marking a year-over-year increase of 17112.68%. This contributed to the annual value of $274000.0 for FY2024, which is 20109.89% up from last year.
  • Lisata Therapeutics' Gains from Investment Securities amounted to $10000.0 in Q2 2025.
  • In the past 5 years, Lisata Therapeutics' Gains from Investment Securities registered a high of $243000.0 during Q1 2025, and its lowest value of $6000.0 during Q3 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $108500.0 (2023), whereas its average is $103000.0.
  • As far as peak fluctuations go, Lisata Therapeutics' Gains from Investment Securities soared by 6705.88% in 2024, and later soared by 7112.68% in 2025.
  • Over the past 3 years, Lisata Therapeutics' Gains from Investment Securities (Quarter) stood at $6000.0 in 2023, then skyrocketed by 2100.0% to $132000.0 in 2024, then tumbled by 92.42% to $10000.0 in 2025.
  • Its Gains from Investment Securities was $10000.0 in Q2 2025, compared to $243000.0 in Q1 2025 and $132000.0 in Q4 2024.